Acción HEMISPHERX BIOPHARMA, INC
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Hemispherx BioPharma, Inc Nyse

Acciones

US42366C3016

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
Challenges To Advance Notice Bylaws Are Spiking
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
North American Morning Briefing : Stocks Seen -2-
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción AIM
  4. Acción
  5. Noticias Hemispherx BioPharma, Inc
  6. Otros idiomas